Lege Artis Medicinae

[COMETS]

MATOS Lajos

APRIL 21, 2006

Lege Artis Medicinae - 2006;16(04)

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[SOME FORMS OF SECONDARY OSTEOPOROSIS: DIAGNOSIS AND TREATMENT]

GENTI György, PÉNTEK Márta, LICKER-FÓRIS Edit

[Secondary causes of bone loss are not often considered in patients, who are diagnosed as having osteoporosis. There are many causes of secondary osteoporosis, including endocrine diseases, renal disorders, transplantation, glucocorticoid therapy, inflammatory rheumatic diseases etc. This article gives an overview on the most frequent and in the everyday practice important forms of secondary osteoporosis. The first principle is the correct diagnosis and the adequate treatment of the underlying disease. In the prevention and treatment of secondary bone loss similar principles are followed as in the primary forms. Calcium, Vitamin D, personalized, well-aimed physical therapy and continuous physical activity are the basic treatment of secondary osteoporosis. Active form of Vitamin D, which does not require calcium combination, has to be applied in advanced age, in impaired renal function, and in case of ineffective therapy with cholecalciferol. Evidence based data suggest that bisphosphonates (alendronate and risedronate) are the most effective antiresorptive agents in the prevention and treatment of glucocorticoid- induced osteoporosis and in osteoporosis associated with rheumatoid arthritis. To prevent secondary hyperthyreoidism during bisphosphonate treatment, a calcium intake of 1000 1500 mg/d and an 800 IU/d of cholecalciferol are recommended. Ibandronate (150 mg once a month), a new bisphosphonate will be available soon. Parathyroid hormone (teriparatide) is an anabolic agent, that enhances bone formation. Its recent introduction offers new options in the treatment of patients with established osteoporosis.]

Lege Artis Medicinae

[CARDIOMETABOLIC EFFECTS OF THE ANGIOTENSIN RECEPTOR BLOCKER TELMISARTAN]

WINKLER Gábor

[Telmisartan, an angiotensin receptor blocker, is a potent antihypertensive drug. Similarly to other members of the drug family, it has cardio-, vasoand renoprotective properties; in addition, uniquely in the group, it stimulates the peroxisome proliferator activated receptor (PPAR) -γ. This partial agonist activity results in favourable effects mainly in carbohydrate metabolism and, to a lesser extent, in lipid metabolism. Based on this pharmacological profile, telmisartan seems to be especially useful in the treatment of hypertension associated with metabolic syndrome or type 2 diabetes.]

Lege Artis Medicinae

[The Patent System: is it For or Against Us? ]

VARGA Orsolya, MOLNÁR Péter

Lege Artis Medicinae

[THE EFFECT OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ON LEFT VENTRICULAR HYPERTORPHY]

KELTAI Mátyás

[This study reviews recent clinical data on the development of left ventricular hypertrophy. Several studies have confirmed that left ventricular hypertrophy is associated with an increased mortality and cardiovascular risk. Most antihypertensive drugs provide some regression of left ventricular hypertrophy, but their efficiency varies. Regression can most efficiently be achieved by the use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers.]

Lege Artis Medicinae

[The True Salieri]

MALINA János

All articles in the issue

Related contents